Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells

Cancer Gene Therapy

Volumn 9, Issue 1, 2002, Pages 87-95

  Burrows, Francis J ^a,c   Gore, Martin ^a,d   Smiley, W Russell ^a,c   Kanemitsu, Martha Y ^a,d   Jolly, Douglas J ^a,e   Read, Susana B ^b   Nicholas, Thomas ^b   Kruse, Carol A ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF COLORADO   (United States)

^c BIOGEN   (United States)

^d ARENA PHARMACEUTICALS   (United States)

^e Biomedica Inc   (United States)

Author keywords

Bystander effect; Colorectal cancer; Connexin; Gap junctions; Glioma; Melanoma; Suicide gene therapy

Indexed keywords

CONNEXIN 43; DYE; GANCICLOVIR; GAP JUNCTION PROTEIN; THYMIDINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CELL COMMUNICATION; CELL CONTACT; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; GAP JUNCTION; GENE THERAPY; GENETIC TRANSFECTION; GLIOMA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETROVIRUS; SUICIDE GENE;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; BYSTANDER EFFECT; CELL COMMUNICATION; COLORECTAL NEOPLASMS; CONNEXINS; GANCICLOVIR; GAP JUNCTIONS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; MELANOMA; MICE; MICE, INBRED BALB C; RETROVIRIDAE; SKIN NEOPLASMS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 85047698025     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700401     Document Type: Article

References (38)

1. Brain tumors
2. Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas
3. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
4. Genetic approaches for the therapy of malignant brain tumors
5. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
6. Bystander tumoricidal effect in the treatment of experimental brain tumors
7. Regulation of connexin-43 gap junctional intercellular communication by mitogen-activated protein kinase
8. Metabolic co-operation between biochemically marked mammalian cells in tissue culture
9. Purified Herpes simplex thymidine kinase Retrovector™ particles: I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy treated brain tumors
10. Purified herpes simplex thymidine kinase retroviral particles: II. Influence of clinical parameters and bystander killing mechanisms
11. Tyrosine phosphorylation of connexin 43 by v-Src is mediated by SH2 and SH3 domain interactions
12. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
13. In situ retroviral-mediated gene transfer for the treatment of brain tumors
14. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro
15. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo
16. Protein and messenger RNA expression of connexin43 in astrocytomas: Implications in brain tumor gene therapy
17. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells
18. Further evidence for the involvement of gap-junctional intercellular communication in induction and maintenance of transformed foci in BALB/c 3T3 cells
19. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions
20. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions
21. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells
22. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
23. Tentative novel mechanism of the bystander effect in glioma gene therapy with HSV-TK/GCV system
24. The "bystander effect": Association of U-87 cell death with ganciclovirmediated apoptosis of nearby cells and lack of effect in athymic mice
25. A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect
26. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: Effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions
27. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo
28. Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect."
29. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL2, IL-6 or B7-1
30. In vivo analysis of the "bystander effect": A cytokine cascade
31. Expression of costimulatory molecules: B7 and ICAM upregulation after treatment with a suicide gene
32. The role of cytokines in mediating the bystander effect using HSV-TK xenogenic cells
33. Potentiation of the bystander effect by immunization combined with suicide gene therapy
34. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma
35. Immune system in suicide-gene therapy
36. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats
37. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells